Main Uses of Dicloftil 0.1%

Dicloftil 0.1% is an ophthalmic solution containing diclofenac sodium, a non-steroidal anti-inflammatory drug (NSAID). It is primarily used to manage ocular inflammation and pain associated with specific surgical procedures and certain non-infectious inflammatory conditions of the eye.

Post-Surgical Inflammation and Pain

The most common application of these eye drops is in the context of ophthalmic surgery. It is frequently indicated for:

• Cataract Surgery: To reduce inflammation and prevent pain following the removal of a cataract.
• Refractive Surgery: To manage postoperative pain and light sensitivity following laser-based vision correction procedures.
• Other Ocular Procedures: To control inflammatory responses after various surgical interventions on the anterior segment of the eye.

Inhibition of Intraoperative Miosis

During cataract surgery, it is often necessary to keep the pupil dilated (mydriasis). Dicloftil 0.1% may be used to help maintain this dilation by inhibiting miosis (pupil constriction) that can occur during the surgical procedure.

Non-Infectious Inflammatory Conditions

Beyond surgical use, the solution may be indicated for the symptomatic treatment of inflammation in non-infectious contexts, such as:

• Post-Traumatic Inflammation: Reducing swelling and pain following non-penetrating injuries to the eye.
• Chronic Non-Infectious Eye Inflammation: Managing discomfort and redness in specific inflammatory states not caused by bacteria or viruses.

Benefits of Treatment

By targeting the underlying inflammatory process, Dicloftil 0.1% provides several clinical benefits focused on patient comfort and recovery:

• Reduction of Edema: It helps decrease swelling of the ocular tissues, including the stabilization of the blood-aqueous barrier.
• Pain Management: It provides effective relief from ocular soreness, grittiness, and aching associated with tissue trauma.
• Improved Recovery: By controlling the inflammatory cascade, it supports a more stable environment for the eye to heal after surgical or traumatic events.

Regulatory References

1. NIH DailyMed Drug Information

Official Eligibility Profile for Dicloftil 0.1%

Dicloftil 0.1% is officially intended for use by adults (18 years and older) who are not subject to any contraindications. Use in geriatric patients is generally comparable to younger adults and does not require a specific dose adjustment.

---

Eligibility Scope	Regulatory Status	Details
Contraindicated Populations	Contraindicated	Patients with known hypersensitivity to Diclofenac Sodium or any component, or those with a history of asthma, urticaria, or acute rhinitis after taking aspirin or other NSAIDs.
Age Restrictions	Not Established	Safety and efficacy have not been established in children younger than 2 years of age. Use in older pediatric populations is generally not recommended.
Pregnancy	Contraindicated	Use is prohibited during the third trimester of pregnancy. Use in the first and second trimesters is permitted with caution.
Lactation (Breastfeeding)	Use with Caution	Permitted with caution due to the expected minimal systemic absorption from the eye drops.

---

Condition-Specific Limitations

The label requires caution in patients with a pre-existing tendency for bleeding or those concurrently receiving anticoagulant medications. Conditional use is also specified for patients with certain corneal conditions (e.g., epithelial defects, denervation) or those who have had complicated ocular surgery. There are no specific labeled restrictions for use in patients with renal or hepatic impairment due to the drug’s topical application and minimal systemic exposure.

As with any medication, Dicloftil 0.1% (diclofenac sodium ophthalmic solution) has the potential to interact with other drugs, even though the amount of medicine absorbed into the bloodstream from eye drops is generally low.

It is essential to inform your doctor or pharmacist of all prescription, non-prescription, and herbal products you are currently using, especially those listed below:

Other Ophthalmic Medications

When using Dicloftil 0.1% with other eye drops or ointments, an interval of at least 5 to 10 minutes should be left between applications to ensure each medication is properly absorbed. If you are using topical eye steroids (corticosteroids) like dexamethasone, the combined use with Dicloftil may increase the potential for slowed or delayed corneal healing. Your healthcare provider will monitor you closely if this combination is necessary.

Systemic Medications

While systemic absorption is minimal, caution is advised if you are taking medications that affect blood clotting, as diclofenac, an NSAID, can also affect platelet aggregation. The risk of bleeding in the eye or elsewhere may be increased when Dicloftil is used alongside:

• Anticoagulants (e.g., warfarin, apixaban, rivaroxaban)
• Antiplatelet agents (e.g., aspirin, clopidogrel)
• Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) taken by mouth (e.g., ibuprofen, naproxen). Combining NSAID eye drops with oral NSAIDs offers no additional benefit but may increase the risk of systemic side effects.

Always discuss your full medication list with your ophthalmologist before starting treatment.

Inhibition of Prostaglandin Biosynthesis

The core mechanism involves the inhibition of the Cyclooxygenase (COX) enzyme system, targeting both COX-1 and COX-2 isoforms. Diclofenac achieves this by binding reversibly to the active site of these enzymes, thereby preventing the metabolism of arachidonic acid into pro-inflammatory prostaglandins. This action modifies the initial molecular steps of the inflammatory cascade, resulting in a reduction in the concentration of these chemical mediators within the eye.

---

Modulation of Local Physiological Responses

By reducing prostaglandin levels, the drug directly alters key downstream physiological consequences. The decreased presence of these mediators limits the sensitization of ocular pain-sensing nerve endings (nociceptors) and attenuates the prostaglandin-driven effects on local blood vessels, such as vasodilation and increased capillary permeability. This peripheral mechanism influences neural and vascular responses by attenuating excessive signaling induced by local injury or stimuli.

How to use Dicloftil 0.1% — Official Administration Guidelines

Dicloftil 0.1% (diclofenac sodium ophthalmic solution) is for topical use only and must be administered by instillation into the conjunctival sac of the affected eye(s). This medicine is typically reserved for adults, with use and dose in pediatric patients requiring determination by a healthcare provider.

Dosing and Frequency by Procedure

Procedure Context	Dosing Schedule
Post-Cataract Surgery	One drop in the affected eye, four times daily, starting 24 hours after surgery and continuing for the first two weeks of the postoperative period.
Corneal Refractive Surgery	One or two drops in the operative eye within the hour prior to surgery. Then, one or two drops within 15 minutes after surgery, and continued four times daily for up to three days.

Required Administration Steps

The following procedural steps must be followed exactly as stated in the official instructions to ensure proper use and contamination prevention:

1. Hand Hygiene: Wash hands thoroughly with soap and water before using the drops.
2. Contact Lenses: Soft contact lenses must be removed before application and may be reinserted 15 minutes afterward.
3. Application: Tilt the head back, gently pull down the lower eyelid to create a small pocket, and hold the container tip near the eye without touching the eye or any surface.
4. Instillation: Instill the prescribed single drop into the lower eyelid pocket.
5. Post-Dose: Immediately after dropping, gently close the eye and apply light pressure to the inner corner of the eye (near the nose) for one to two minutes. This technique, known as nasolacrimal occlusion, is recommended to increase local effect and reduce systemic absorption.
6. Multiple Drops: If using another type of eye medication, wait at least five minutes between each application.

Missed Dose: If a dose is missed, apply it as soon as remembered. If it is almost time for the next scheduled dose, skip the missed dose and return to the regular schedule. Do not double the dose to catch up.

Dicloftil 0.1%: Recent Clinical Evidence

This summary outlines the structure of available clinical research for Dicloftil 0.1% (Diclofenac Sodium Ophthalmic Solution) based on findings reported in scientific studies, without making any claims regarding efficacy, benefit, or clinical guidance.

---

Evidence for Managing Inflammation After Cataract Surgery

Research has explored the use of Dicloftil 0.1% eye drops in people following cataract extraction surgery. These are primarily Randomized Controlled Trials (RCTs) where the solution was studied against an inactive placebo or other anti-inflammatory drops. Studies have examined outcomes linked to inflammatory or irritative states such as measured changes in anterior chamber cell and flare scores and the condition of the retina (to assess post-operative swelling or CME) over periods up to a few months.

---

Studies on Acute Pain Following Corneal Procedures

Research has explored the use of this topical solution in studies examining acute symptoms following corneal refractive surgeries, such as PRK. This evidence is based on short-term RCTs that focused on episodes where symptoms become more noticeable immediately after the procedure. Studies evaluated patient-reported outcomes describing perceived discomfort, including the intensity of ocular pain and light sensitivity in the first few days post-operation. Findings describe group patterns related to these short-term symptom changes.

---

Research on Maintaining Pupil Diameter During Eye Surgery

This medication was evaluated in studies that examined its application before and during cataract surgery to see if it was associated with the maintenance of the pupil size. Research examined temporary physiological imbalance, and data show patterns related to the objective measurement of the pupil's diameter during critical surgical stages. Certainty remains low for this specific endpoint as it is often evaluated as a secondary goal in trials primarily focused on post-operative inflammation.

---

Research Gaps and Areas of Uncertainty

Long-term effects are not fully established for any studied indication, as follow-up durations were limited, typically focusing on the immediate post-procedure phase rather than patterns that may arise after several months. For non-surgical inflammation (such as acute trauma), the evidence is limited, relying mostly on observational data rather than dedicated high-quality RCTs. Furthermore, data for specific subgroups, such as pediatric patients or people with certain pre-existing conditions, are uncertain due to smaller sample sizes or limited representation in the core clinical trials.

Key Studies & References

1. Diclofenac sodium solution - DailyMed (National Library of Medicine / FDA Labeling)
2. Macular Alteration of Topical Diclofenac Sodium after Phacoemulsification Surgery in Diabetic Patients (Subgroup Evidence)

Common questions about Dicloftil 0.1% (FAQ)

---

Q: What is the active ingredient in Dicloftil 0.1%?

The active ingredient in Dicloftil 0.1% is diclofenac sodium, which belongs to the class of non-steroidal anti-inflammatory drugs (NSAIDs). According to the official product information, this ingredient provides the medicine's anti-inflammatory and pain-relieving effect. The concentration of this active substance in the eye drop formulation is 0.1%.

---

Q: What is Dicloftil 0.1% used for?

Dicloftil 0.1% eye drops are indicated for specific ophthalmic applications, as defined in regulatory documents. These include the inhibition of miosis (pupil constriction) during cataract surgery and the management of inflammation following certain eye operations. It is also indicated for the treatment of pain and inflammation that occurs after a non-infectious injury to the cornea (corneal trauma).

---

Q: Can I use Dicloftil 0.1% to treat pain from a headache or body ache?

No, Dicloftil 0.1% is formulated as an ophthalmic solution, meaning it is designed only for use in the eye. The regulatory documents confirm its indications are strictly limited to treating specific conditions affecting the eye, such as post-operative inflammation and corneal trauma. It is not intended for the relief of general aches, pains, or headaches elsewhere in the body.

---

Q: What should I do if I miss a dose of Dicloftil 0.1%?

Official product information describes the general guidance when a dose is missed. Instructions indicate that if an application is forgotten, it is usually recommended to apply it as soon as the patient remembers, unless it is nearly time for the next scheduled dose. Regulatory guidance typically advises not to apply a double dose to compensate for the missed one.

---

Q: How long can I use Dicloftil 0.1% eye drops?

The appropriate duration of treatment with Dicloftil 0.1% is determined by the specific eye condition being addressed. For example, regulatory documents often specify that treatment following certain ocular procedures may be limited to a period of only a few days. The official product information specifies the recommended maximum duration of use for each indicated condition.

---

Q: Is it safe to wear contact lenses while using Dicloftil 0.1%?

According to the official product information, the use of soft contact lenses is generally not compatible with this medicine. The drops contain benzalkonium chloride, which can be absorbed by soft lenses and may potentially cause discoloration. Regulatory guidance suggests removing soft contact lenses before application and waiting a designated time before reinserting them.

---

Q: What is benzalkonium chloride, and why is it in the eye drops?

Benzalkonium chloride is listed in the official product documents as an excipient, which is an inactive ingredient in the formulation. It functions as a preservative in the solution to help prevent the growth of microorganisms after the bottle is opened. Official regulatory sources highlight that this substance is the reason soft contact lenses should not be worn during treatment.

---

Q: How long can I keep the bottle of Dicloftil 0.1% after opening it?

Official product information specifies a limited duration of use once the eye drops container has been opened for the first time. To help maintain sterility and quality, regulatory sources state that the solution must be discarded four weeks after initial opening. This instruction applies even if there is still product remaining in the bottle.

How to Store and Dispose of Dicloftil 0.1%

Storage Requirements

Dicloftil 0.1% (Diclofenac Sodium Ophthalmic Solution) must be stored at controlled room temperature, generally between 15°C and 30°C (59°F and 86°F), as specified in regulatory labeling. It is mandatory to Keep from freezing and to Protect from light. The container must be kept tightly closed when not in use. To maintain sterility, avoid touching the applicator tip to any surface. For safety, the medicine must always be stored out of the reach and sight of children.

Disposal Instructions

Regulatory instructions for disposal require consulting a healthcare professional or pharmacist on how to discard unused or expired product. This guidance must be followed to avoid disposal in household trash or wastewater, which helps protect the environment.